Drug Trial Radar · NCT06698549
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Feb 20, 2025
Primary completion
Jul 23, 2025
Study completion Aug 13, 2025
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Nov 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects without renal impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
Conditions
- COVID 19
Interventions
ALG-097558Drug
Multiple doses of ALG-097558 300 mg (3 x 100 mg tablets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration Time Curve [AUC]Time frame: AUC(0-12): Pre-dose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12h post last dose on days 1 and 6; AUC(0-last): Predose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12h post last dose on day 1 and 6, and additionally 14, 24, 36 and 48h on day 6 only
- Maximum Plasma Concentration [Cmax]Time frame: Pre-dose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post last dose on day 1 ; Pre-dose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post last dose on day 6
- Minimum Plasma Concentration [Cmin]Time frame: Pre-dose (-0.75 hours), 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post last dose on day 6 only
- C0 [Predose]Time frame: Pre-dose (-0.75 hours) up to Day 8
- Half-life [t1/2]Time frame: Pre-dose (-0.75 hours), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post last dose on day 6 only
- Time to Maximum Plasma Concentration [Tmax]Time frame: Pre-dose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post last dose on day 1 ; Pre-dose (-0.75), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post last dose on day 6
- Apparent Clearance (CL/F)Time frame: Pre-dose (-0.75 hours), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post last dose on day 6 only
- Apparent Volume of Distribution (V/F)Time frame: Pre-dose (-0.75 hours), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48 hours post last dose on day 6 only
- Total Amount of Drug Excreted in Urine (Ae)Time frame: Collection intervals: 0-6, 6-12, 12-24, 24-36 and 36-48 hours after the last dose
- Renal Clearance (CLr)Time frame: Collection intervals: 0-6, 6-12, 12-24, 24-36 and 36-48 hours after the last dose.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Genesis Clinical Trials
Tampa, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.